Daewoong Pharma: supply contract with Abbott Products terminated
Daewoong Pharma reported the termination of a supply contract with ABBOTT PRODUCTS OPERATIONS AG (Switzerland), with a contract amount of ₩69.2bn. The filing states the amount as 8.2% of revenue. The termination date was Feb 28, 2024.
Key facts
| Event | Contract terminated |
|---|---|
| Counterparty | ABBOTT PRODUCTS OPERATIONS AG (Switzerland) |
| Terminated contract amount | ₩69.2bn |
| % of revenue (as reported) | 8.2% |
| Termination date | Feb 28, 2024 |
Comparison
| Amount as % of FY2025 revenue (calculated) | 4.4% |
|---|---|
| Revenue 2025 | ₩1.6tn |
| Revenue 2024 | ₩1.4tn |
| Revenue 2023 | ₩1.4tn |
Context
In the 12 months before this filing, the company filed 1 supply contract disclosure, with a total of ₩92.6bn.
Key metrics
Supply contracts
| Supply contracts, last 12 months | ₩92.6bn |
|---|---|
| Supply contracts vs prior-year revenue | 5.9% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗